TNGNQ (Tengion) EBITDA Margin %: 0.00% (As of Sep. 2014)


What is Tengion EBITDA Margin %?

Tengion TNGNQ -99.00% EBITDA Margin % is 0.00% as of Sep. 2014.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tengion's EBITDA for the three months ended in Sep. 2014 was $-16.44 Mil. Tengion's Revenue for the three months ended in Sep. 2014 was $0.00 Mil. Therefore, Tengion's EBITDA margin for the quarter that ended in Sep. 2014 was 0.00%.

Tengion  (OTCPK:TNGNQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Tengion EBITDA Margin % Related Terms

Tengion EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Tengion's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tengion EBITDA Margin % Chart

Tengion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tengion Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TNGNQ vs VITIF, HSTC, NTRR: EBITDA Margin % Comparison

For the Biotechnology subindustry, Tengion's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tengion EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Tengion's EBITDA Margin % falls into.


Tengion EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Tengion's EBITDA Margin % for the fiscal year that ended in Dec. 2013 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2013 )/Revenue (A: Dec. 2013 )
=-11.038/0
= %

Tengion's EBITDA Margin % for the quarter that ended in Sep. 2014 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2014 )/Revenue (Q: Sep. 2014 )
=-16.438/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Tengion (TNGNQ) has a EBITDA Margin % of 0.00% as of Sep. 2014. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tengion and its competitors.
Is Tengion's EBITDA Margin % too high?
Tengion's current EBITDA Margin % is 0.00%.
How does Tengion's EBITDA Margin % compare to VITIF and HSTC?
Tengion's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tengion and its competitors. Tengion's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tengion stock overvalued right now?
Tengion (TNGNQ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tengion (TNGNQ), the current EBITDA Margin % is 0.00% as of Sep. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tengion Business Description

Address 3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.